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280 abstract
Growing healthcare expenditure is of major concern for the sustainability of 
public finances. In order to better explore the fiscal sustainability challenge and 
to inform the debate, we draw up a new set of healthcare expenditure projections 
for the particularly interesting case of Switzerland. According to our projections 
up to 2045, population ageing exerts a growing pressure on public budgets and 
mandatory healthcare insurance. However, healthcare expenditure is not only 
driven by demographic change but also by non-demographic drivers such as the 
increasing national income, medical advances and Baumol’s cost disease. We find 
that long-term care is more severely affected than healthcare excluding long-term 
care. This finding implies that population ageing affects public finances to a 
greater extent than the mandatory healthcare insurance. Our sensitivity analysis 
suggests that the strongest cost pressure comes from alternative assumptions 
about the future state of health and Baumol’s cost disease. Accordingly, measures 
aiming at prevention and efficiency would help most to ease the pressure on public 
finances and mandatory healthcare insurance.
Keywords: healthcare expenditure growth, population ageing, long-term projec-
tions, sustainability, public finances, social insurance
1 IntRoDUctIon
Across most advanced economies, health care expenditure has clearly outpaced 
economic growth in recent decades. This development is particularly evident in 
the US and in several European countries. While the US notably spends almost 
17% of its income on healthcare, several European countries follow with the GDP 
share in question currently being at 12.1% in Switzerland, 11.2% in Germany and 
11.1% in France (see figure 1).
Figure 1
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281In order to better explore the fiscal sustainability challenge and to inform the pol-
icy debate about measures to contain healthcare expenditure, we present a net set 
of projections focusing of the particularly interesting case of Switzerland. Swit-
zerland has one of the most expensive healthcare systems among OECD countries 
and features a highly decentralized healthcare system. Moreover, the Swiss health-
care system is characterized by a particular financing scheme, i.e. a mixture of a 
mandatory (private) health insurance scheme and a relatively high share of public 
financing and private cost sharing.
Healthcare expenditure (HCE) in Switzerland has more than doubled over the last 
half-century or so, rising from 5.2% of GDP in 1960 to 12.1% of GDP in 2015. 
While the annual average growth rate of GDP per capita amounted to 1.5%, HCE 
per capita grew at a rate of 3.4%. A decomposition of HCE by funding source 
shows that public finances and, in particular, the expenditure of the mandatory 
healthcare insurance (MHI) have come under increasing pressure from the rise of 
HCE (see figure 2). 
Figure 2
Per-capita healthcare expenditure by funding source and per-capita GDP from 











































HCE Mandatory Health Insurance Healthcare expenditure (HCE)
Public HCE (incl. social security) GDP
Source: Federal Statistical Office and Federal Finance Administration.
In this paper, we include a set of important drivers of HCE, i.e. ageing, income, 
medical progress as well as Baumol’s cost disease for the projections. In all likeli-
hood, population ageing increases the pressure on healthcare funding. Although 
the relative importance of population ageing as a determinant of HCE has been 
contested by some health economists (Zweifel, Felder and Meiers, 1999; Werblow, 
Felder and Zweifel, 2007), there is growing evidence for the relevance of popula-
tion ageing as a driver of HCE (Gregersen, 2014; Breyer, Lorenz and Niebel, 
2015; Colombier, 2018). Smith, Newhouse and Freeland, (2009:1281) explain 
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282 spending but will loom larger with the ageing of baby boomers”. An ageing popu-
lation does not only exhibit greater demand for healthcare services and greater 
need for care services, but it also causes GDP growth to slow down because of the 
diminishing labour force. These developments are reflected in the “Reference sce-
nario” of the Swiss Federal Statistical Office (FSO). The proportion of people 
over the age of 80 relative to the population is set to double from the current level 
of 5% to 10% by 2045. A closely related question is how changes in life expec-
tancy affect the health status of the population, thereby impacting HCE. More-
over, we take account of income development, advances in medical technology, 
and Baumol’s cost disease – all determinants viewed as crucial by the literature 
(Martín et al., 2011; de la Maisonneuve and Oliveira Martins, 2013; Hartwig and 
Sturm, 2014). We apply income elasticity as a proxy for demand-side as well as 
supply-side effects, such as the demands of the population and advances in medi-
cal technology. Baumol’s cost disease (Baumol, 1967) concerns the lower produc-
tivity development in healthcare that leads to additional cost pressure. 
We draw up long-term projections of HCE that cover the period from 2013 to 
2045. We use the latest demographic scenarios for Switzerland (FSO). In accord-
ance with the practice of international institutions such as the OECD (de la Mai-
sonneuve and Oliveira Martins, 2013; Marino et al., 2017) and the Ageing Work-
ing Group of the European Union (AWG, 2015), we apply a cohort approach and 
project HCE as a percentage of GDP. For the purposes of these projections, it is 
assumed that the currently prevailing health policies and institutions will not 
change (“no policy change”). Accordingly, while (cross-country) differences in 
the organization of the healthcare sector, e.g. different insurance and financing 
regimes, different compensation systems for providers and the role of general 
practitioner models, are likely to matter for healthcare cost growth, we take the 
existing institutional framework of the Swiss healthcare system as given.
Our projections show that population ageing exerts a growing pressure on public 
budgets and MHI. This development poses a threat to the sustainability of public 
finances (Braendle, Colombier and Philipona, 2016). However, not only does 
demographic change impact HCE but also non-demographic drivers such as the 
increasing national income and medical advances as well as Baumol’s cost disease 
play a significant role. The results of this paper are comparable to those of the 
OECD (de la Maisonneuve and Oliveira Martins, 2013) and the EU AWG (2015). 
In particular, we find that long-term care (LTC) from the age of 65 is more severely 
affected than healthcare excluding long-term care (HeL). This finding implies that 
population ageing affects public finances to a greater extent than it does affect 
MHI. A side-effect of continuously rising MHI premiums is undesirable distribu-
tional consequences. The financial burden of lump-sum per capita premiums is 
increasing for an ever-larger part of the population. Public finances are also 
adversely affected by premium increases through rising social benefits, i.e. indi-
vidual premium reductions (IPR) to guarantee equal access to healthcare services 
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283ures that increase the efficiency of healthcare provision such as the avoidance of 
medically unnecessary treatments, a stronger reliance on capitation-based remu-
neration schemes, the introduction of E-health, allocation improvement between 
outpatient and inpatient care and fostering ambulatory and informal care can 
mitigate the pressure on MHI and public budgets. In addition, preventive meas-
ures and strengthening of the population’s health competencies can contain HCE 
and ease, in particular, the pressure on public budgets. The projections are charac-
terised by significant uncertainties such as the magnitude of the cost effects, and 
the modelling of non-demographic determinants in the healthcare system. The 
latter is particularly true for advances in medical technology. The objective is to 
provide a rough orientation for expenditure development and to highlight how 
sensitively expenditure development reacts to various cost drivers. For that reason, 
scenarios have been drawn up with differing assumptions regarding the impact of 
the relevant cost drivers. 
This paper is organised as follows. Section 2 discusses the key cost drivers and 
describes the various scenarios. Section 3 sets out the projection methodology. 
Section 4 presents the main results of the projections for the total healthcare sec-
tor, the public sector and the mandatory insurance. Moreover, a comparison is 
drawn with the results for EU member countries. In concluding, section 5 dis-
cusses policy options to contain cost development in healthcare. 
2 DeteRMInants anD scenaRIos
2.1 cost DRIVeRs
In addition to the immediate repercussions of demographic change for healthcare 
expenditure, we include those effects that can have an expenditure impact as a 
result of a change in the health status (morbidity) due to increasing longevity. A 
number of different competing hypotheses have emerged in this respect. Accord-
ing to the thesis of pure morbidity extension, so-called “pure ageing”, the addi-
tionally gained years of life are not spent in good health (Gruenberg, 1977). The 
state of health of the population deteriorates on average. The thesis of a relative 
reduction in morbidity, so-called “healthy ageing”, states that the amount of time 
spent in a state of illness or in need of care does not change. However, it is also 
claimed that the extra years of life gained are spent in a good state of health (Man-
ton, 1982). The thesis of an absolute reduction in morbidity in the event of rising 
life expectancy is put forward by Fries (1980, 1989), who argues that as a result of 
better technology and better prevention, the amount of a person’s lifetime spent in 
sickness or in need of care can actually be reduced. The amount of time spent in 
good health rises more strongly than life expectancy. As there is no clear consen-
sus in empirical studies with respect to the interaction of rising life expectancy 
and morbidity development, scenarios with different assumptions regarding the 
change in morbidity have been drawn up.
 
Aside from the effects of demographic change, the projections also include the 
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284 factor to be taken into consideration is the empirically observable relationship 
between national income development and healthcare expenditure growth. This 
relationship covers both supply-side and demand-side effects, such as advances in 
medical technology and the demand of the population for healthcare services. 
As advances in medical technology are very difficult to quantify from an empiri-
cal standpoint, it is assumed that the cost effect of advances in medical technology 
can be indirectly captured through the change in national income development. 
According to Smith, Newhouse and Freeland (2009), close interdependencies ex-
ist between advances in medical technology and national income: as a society 
becomes more prosperous, it may be assumed that its demand for medical innova-
tions will rise (“demand pull”). At the same time, as a society becomes increas-
ingly prosperous, so too is there an increase in selling opportunities for healthcare 
services, which has the effect of increasing the incentive to invest in research and 
development (“supply push”). Chandra and Skinner (2012) emphasize that medi-
cal advances can be converted into productivity gains if innovations are highly 
cost effective and effective new procedures are not overused. At the same time, 
treatments with uncertain and ineffective outcomes decelerate productivity growth 
and lead to increasing costs. 
A key question is whether the demand for healthcare services (and therefore 
healthcare expenditure) rises disproportionately to income, thereby making 
healthcare services a so-called “luxury good”. Early empirical analyses suggest 
that healthcare expenditure represents a so-called “necessary good” at an indi-
vidual and a “luxury good” at an aggregated level (Gerdtham and Jönsson, 2000). 
However, there is no clear consensus on a precise assessment of income elasticity 
at aggregated level. Underlying problems are the comparability of the definitions 
of healthcare expenditure categories or the possible correlation of input prices and 
national income. Recent studies are often based on more comprehensive databases 
and use advanced empirical methods in order to address problems such as the 
omitted variable bias and endogeneity. These studies typically suggest an income 
elasticity of slightly below 1 (Baltagi and Moscone, 2010; Moscone and Tosetti, 
2010; Costa-Font, Gemmill and Rubert, 2011; Acemoglu, Finkelstein and Noto-
widigdo, 2012; de la Maisonneuve and Oliveira Martins, 2013; Medeiros and 
Schwierz, 2013; Hartwig and Sturm, 2014). In the case of Switzerland, Colombier 
(2018) uses a time series analysis for total HCE to show a systematic, positive 
partial correlation with national income, whereby the corresponding income elas-
ticity is around 1. For a cantonal panel dataset for the period 1970-2012, Braendle 
and Colombier (2016) find – in keeping with the results of the latest research lit-
erature – a robust partial correlation between income and cantonal healthcare 
expenditure, whereby the estimated income elasticity lies around 0.7 to 0.8. Vatter 
and Rüefli (2003), who investigate the determinants of healthcare expenditure for 
a cross-section of cantons and communes for the years 1994-1999, find a positive 
partial correlation between cantonal income and public healthcare expenditure. 
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285cant partial correlation. Crivelli, Filippini and Mosca (2006), and Reich et al. 
(2012) investigate the sum of cantonal healthcare expenditure and MHI expendi-
ture at cantonal level. For a significantly shorter timeframe, namely 1996 to 2002 
or 1997 to 2007 (due to the incorporation of MHI data), these studies do not find a 
statistically significantly positive correlation between cantonal income and HCE. 
Another factor concerns productivity development in healthcare. This is difficult 
to measure empirically, and may indeed differ among healthcare sectors. For 
example, productivity advances in labour-intensive long-term care may be mini-
mal, whereas in the more capital-intensive and technology-intensive hospital sec-
tor, productivity gains could reasonably be expected. Lower productivity growth 
relative to the overall economy results in cost pressure if healthcare wages keep 
step with wage growth in the remainder of the economy in the longer term. Given 
a relatively inelastic demand for healthcare services, healthcare prices accord-
ingly rise more strongly than prices in the remaining economy. This price effect is 
known as Baumol’s cost disease (Baumol, 1967). Empirical studies provide evi-
dence that the Baumol effect is an important determinant of HCE (Colombier, 
2017). However, the evidence regarding the extent of the Baumol effect is mixed. 
Some panel data analyses for OECD countries come to the conclusion that health-
care is completely contracted by the cost disease (Hartwig, 2008; Hartwig and 
Sturm, 2014). Based on a refined approach, Bates and Santerre (2013) for the US 
federal states and Colombier (2017) for OECD countries show that the cost dis-
ease is only partially relevant in healthcare. The same conclusion is reached by 
Colombier (2018) who uses time-series data from Switzerland. 
Studies based on micro data provide evidence for the primary relevance of the 
proximity to death for healthcare costs (Zweifel, Felder and Meiers, 1999; Felder, 
Meier and Schmitt, 2000; Werblow, Felder and Zweifel, 2007). They suggest that 
population ageing per se barely affects HCE. While the proximity to death is rel-
evant at the microeconomic level, its relative importance at macroeconomic level 
and, thus, for projection HCE is contested for the following reasons (e.g. de la 
Maisonneuve and Oliveira Martins, 2013). First, empirical evidence shows that 
the results of HCE projections do not substantially change if the proximity to 
death is included (Colombier and Weber, 2011; van Baal and Wong, 2012). Sec-
ond, methodological concerns have been raised, such as the endogeneity between 
the explanatory variable proximity to death and HCE (Gregersen, 2014). Further-
more, ageing as a determinant becomes more relevant if a time-series dimension 
is added and ageing over time, a rising longevity, is included (Breyer, Lorenz and 
Niebel, 2015).
Differences in the organization of the healthcare sector, e.g. different insurance 
and financing regimes, different compensation schemes for providers, different 
regulations of healthcare markets and the role of general practitioner models, are 
likely to matter for healthcare cost growth (Bodenheimer, 2005; Hartwig and 
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286 change assumption, we take the existing institutional framework of the Swiss 
healthcare system as given.
2.2 scenaRIos 
We draw up different scenarios for the sectors of HeL and LTC from the age of 65 
to take the uncertainties regarding the cost impact of the determinants into consid-
eration. 
With respect to the change in the population’s state of health, it is assumed for the 
sector of HeL that the extra years of life gained are spent half in a good state of 
health and half in a poor state of health in the “Reference scenario”. In addition, 
the increase in national income has a disproportionately high impact on the 
increase in healthcare expenditure through demand and supply-side effects. Lean-
ing on the “AWG reference scenario” by AWG (2015:124-25) and empirical re-
sults for Switzerland (Colombier, 2018) an income elasticity of 1.1 is assumed. 
The Baumol effect is not factored into the considerations. Population growth is 
extrapolated in accordance with scenario A-00-2015 of the FSO. In the “Pure age-
ing” scenario, by contrast, it is assumed that the population spends the additional 
years of life gained in a poor state of health (extension of morbidity). In the 
“Healthy ageing” scenario, the population spends the extra years of life gained in 
good health (relative decrease in morbidity). In contrast to the “Reference sce-
nario”, the “Migration” scenario is based on demographic scenario A-06-2015, 
which assumes a higher net immigration rate. Due to the sharper increase in the 
working-age population, economic growth is stronger than in the reference sce-
nario. In the “Baumol” scenario, unlike in the reference scenario, it is assumed 
that productivity advances in healthcare (excluding the long-term care sector) are 
some 40% lower than in the economy as a whole. In the “Expanded Baumol” 
scenario we assume for the sector of HeL a Baumol effect of 60%. The productiv-
ity advance in the sector of HeL lags behind overall economic productivity 
advance by 60%. The long-term care sector experiences a low advance in produc-
tivity (25% of the overall economic average). Only 75% of the Baumol effect 
manifests itself in the long-term care sector. This figure is based on the level of 
staff costs as a proportion of overall costs in the care-home sector (Christian et al., 
2015). In the “Cost pressure” scenario, is it assumed that non-demographic cost 
determinants gain in importance: advances in medical technology, an increase in 
doctor densities with a higher risk of supplier-induced demand given the asym-
metric information between doctors and patients, and the increasing degree to 
which the population draws on healthcare services – trigger significantly stronger 
expenditure growth than in the “Reference scenario”. This in turn translates into 
expenditure rising more strongly in the event of rising income. Based on the cor-
responding European Commission scenario, an income inelasticity of 1.4 is 
assumed (AWG, 2015).
The same assumptions regarding demographics and morbidity (i.e. the need for 
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287age of 65. However, other than in the “Expanded Baumol” scenario, it is assumed 
in the scenarios for long-term care that no productivity advances are achievable, 
and that the Baumol effect is therefore fully effective. This is a standard assump-
tion for projections of HCE (de la Maisonneuve and Oliveira Martins, 2013). In 
addition, no income effect comes into play in the long-term care sector, as the 
need for care is not voluntary and is independent of income. Accordingly, a no 
“Cost pressure” scenario is drawn up for the long-term care sector.
3 MetHoDoloGY1
In accordance with the practice of international institutions such as the OECD and 
the European Commission, we apply a cohort approach and project HCE as a 
percentage of GDP.2
As a number of different cost drivers (or in some cases the same cost drivers) ex-
ercise their influence to a differing extent in different sectors of the healthcare 
system, the expenditure projections for healthcare expenditure are broken down 
into the sectors of HeL and LTC from the age of 65. The residual sector is there-
fore that of long-term care for persons aged under 65. On the basis of this break-
down, the total expenditure of each sector is projected in a first step. In the next 
step, the proportion of healthcare expenditure financed by both the public sector 
and MHI are extrapolated along with the expenditure projected for the total health-
care sector. 
The figures for healthcare expenditure are taken from the FSO’s “Costs and Ser-
vices of the Healthcare System” statistics. The most recent data available at the 
time the projections were drawn up date back to 2013, which is why this year 
forms the base year for the projections. The graphic illustration of expenditure per 
capita of population by age is described as the expenditure profile for a given year. 
For example, in figure 3 the expenditure profile for outpatient treatment in HeL for 
women is shown for the base year and for the year 2045 under the “Healthy age-
ing” scenario. In order to project expenditure for the HeL and LTC sectors, the 
expenditure profiles are further divided up by gender as well as by outpatient and 
inpatient treatment. Expenditure per capita of population can effectively be 
viewed as the price of supplying the population with healthcare services at a given 
level. This expenditure per capita of population can then be broken down into the 
price of services per patient on the one hand, and the scope of service (e.g. treat-
ments, medications) per capita of population on the other.3 It is therefore assumed 
that demographic changes affect neither the cost side nor the scope of service per 
resident side. As a consequence, the cost effect of demographic change expresses 
1 For a detailed description of the projection methodology and the expenditure profiles, see Braendle and 
Colombier (2017:18-25).
2 For a review on projection methodology see Pryzwara (2010).
3 The expenditure per capita by age cohort can be broken down into a price effect and volume effect per patient 
treated on the one hand, and the probability of falling ill on the other: expenditure per service (“price”) x uti-
lisation per patient x patients per capita of an age cohort, whereby the product of utilisation per patient and 
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288 how a change in the ageing structure of the population and the number of residents 
in Switzerland changes total demand for healthcare services. For simplicity’s 
sake, expenditure on long-term care for those aged below 65 is extrapolated on the 
basis of the change in GDP.
Figure 3
Expenditure profile for outpatient treatment of women in HeL by age in the base 


















The starting point for the projections is the expenditure profiles broken down by 
age, gender, and outpatient or inpatient services (see figure 3). If the state of health 
of the population improves over the projection period, the expenditure per capita 
of an age cohort falls, and the expenditure profile shifts to the right (see figure 3). 
Here it is assumed that the probability of falling ill or requiring care declines. At 
the same time, this means that a change in morbidity influences neither the 
expenditure on a medical or care service, nor the degree of utilisation per patient. 
As the probability of falling ill or requiring care falls, however, so too does the 
scope of service per capita for an age cohort. The cost pressure exerted by non-
demographic cost drivers such as advances in medical technology expresses itself 
in rising expenditure per capita of an age cohort. As a similar effect of non-demo-
graphic cost drivers is assumed for all age cohorts, the expenditure profile accord-
ingly shifts upwards.4 This increase in expenditure is either caused by rising 
expenditure per service or by an increasing degree of utilisation per patient, or by 
a combination of the two, and has the effect of increasing the price of providing 
healthcare services. Changes in quality in the provision of services are not taken 
4 There are a number of indications to the effect that the expenditure profile steepens with time, and that the age 
cohorts are therefore affected to different degrees by the cost pressure of non-demographic cost drivers such 
as advances in medical technology (Gregersen, 2014). This could imply, for example, that research efforts to 
develop new medications are particularly focused on medications for the older age cohorts, as old people are 
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289into account in this approach.5 Furthermore, in the sector of HeL, it is assumed 
that expenditure per capita remains constant for the age cohort “96 and over” due 
to limited data availability. In light of major differences in life expectancy at dif-
ferent ages, as well as between women and men, morbidity effects are determined 
not by the change in average life expectancy of the overall population, but by the 
change in life expectancy based on age and gender. 
4 ResUlts
4.1 total HealtHcaRe eXPenDItURe
According to the “Reference scenario”, expenditure will continue to rise from 
10.8% of GDP in 2013 to 14.0% of GDP in 2045 (see figure 4). For the years 1995 
to 2013, health expenditure rose by around 2 percentage points of GDP (whereby 
GDP is cyclically adjusted). The average annual growth rate of total HCE amount-
ed to 3.7%. What is striking is that the annual growth rate of expenditure on LTC 
from the age of 65 outpaced expenditure on HeL by over 1 percentage point, i.e. 
4.8% vs. 3.6%. 
Figure 4
Healthcare expenditure by sector from 1995 to 2013 and in the “Reference scenario” 
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According to the “Reference scenario”, the trend towards significantly higher 
expenditure growth for long-term care (from 65 years of age) than for healthcare 
excluding long-term care will continue in the future. Measured as a percentage of 
GDP, expenditure on long-term care (from the age of 65) more than doubles (ris-
ing from 1.6% to 3.4% of GDP), while healthcare expenditure rises from 8.6% to 
9.9%. On the one hand, demographic change (ageing, including the associated 
5 In the case of a price rise as a result of advances in medical technology, the extent to which the level of pro-
vision rises as a result of quality improvements is not clear. Potential quality improvements would have to be 
offset against the price effect in order to capture the effective price rise. This is an extremely challenging task 
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290 change in the average state of health) feeds through into the long-term care sector 
to a much greater extent (72% of the rise in expenditure) than it does in the 
remaining healthcare sector (just under 60% of the rise in expenditure).6 On the 
other hand, expenditure on long-term care rises by 2.2% annually as a result of the 
Baumol effect, whereas expenditure on healthcare as a result of rising income per 
capita rises by just under 1.9% annually. 
4.2 PUblIc HealtHcaRe eXPenDItURe
Public expenditure on healthcare comprises all contributions of the federal govern-
ment, cantons and communes, as well as the social security funds for financing 
healthcare. For each of the three levels of government, the expenditure figure in 
question is that contained under the “Health” section of the public finance statistics 
by the Federal Finance Administration (FFA). Also included are government trans-
fers to private households designed to finance healthcare benefits, such as individ-
ual premium reductions and cantonal supplementary benefits for the old-age pen-
sions. Furthermore, HCE of the social insurances for old-age (AHV) and disability 
(IV) are included. Just like overall expenditure, public healthcare expenditure is 
broken down into the sectors of healthcare excluding long-term care, and long-
term care from the age of 65. Other public sector contributions to healthcare, such 
as preventive measures and administration, are extrapolated in line with GDP.
The public sector devotes the greatest proportion of its healthcare expenditure to 
hospitals (40%), followed by individual premium reduction (IPR) (19%), AHV 
supplementary benefits for care (9%), care homes (7%), and ambulatory care 
(4%). The remaining contributions come from the social security funds and encom-
pass the AHV allowance for the physically disabled (2%) and IV expenditure on 
healthcare (9%). A striking point to note according to the “Reference scenario” is 
that in 2045 the public sector will have to spend a far greater proportion of its 
budget on long-term care from the age of 65. Instead of the current level of 23%, 
the share of expenditure accounted for by care is projected to rise to 34% in 2045. 
Accordingly, the proportion of expenditure accounted for by healthcare excluding 
long-term care is lower in 2045, having declined from 68% to 61%. 
 
According to the “Reference scenario”, general government expenditure rises 
over the projection timeframe continuously, namely from 3.5% of GDP to 4.2% of 
GDP in 2030, and up to 5.0% of GDP by 2045. The lion’s share of general govern-
ment expenditure here is borne by the cantons, namely 68%. For example, a good 
two thirds of the increase in public healthcare spending up to 2045, or 1.1% of 
GDP, is shouldered by the cantons. Table 1 gives an overview of the projected 
healthcare expenditure growth by source of financing in the “Reference scenario”.
6 For a decomposition of the relative importance of HCE determinants in the various scenarios see appen-
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291Table 1
Expenditure on healthcare by area and source of financing in reference scenario 
(in GDP %)





Total healthcare 10.8 12.2 +1.4 14.0 +3.2
Healthcare excluding long-term care 8.6 9.3 +0.7 9.9 +1.3
Long-term care (from the age of 65) 1.6 2.3 +0.7 3.4 +1.8
Long-term care (below the age of 65) 0.6 0.6 0.0 0.6 0.0
Source of financing
Government (incl. soc. sec. funds) 3.5 4.2 +0.7 5.0 +1.5
Confederation 0.4 0.5 +0.1 0.5 +0.1
Cantons 2.4 2.9 +0.5 3.5 +1.1
Communes 0.3 0.4 +0.1 0.5 +0.2
AHV/IV* 0.4 0.3 -0.0 0.4 +0.0
Mandatory health insurance** 3.3 3.7 +0.4 4.1 +0.8
Other expenditure*** 4.0 4.3 +0.3 4.8 +0.9
of which: private households**** 2.6 2.9 +0.3 3.3 +0.7
* Allowances for the helpless, contributions to medical services and therapeutic equipment.
** Excluding public expenditure on individual premium reductions, which are attributed to the 
general government sector.
*** Other expenditure contains the expenditure of private households, mandatory accident assur-
ance (SUVA) and military insurance, supplementary insurances, private foundations and supple-
mentary benefits of IV, which are not driven by ageing.
**** Cost contribution of OKP and out-of-pocket payments (OOP).
Figure 5
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It can be seen in figure 5 that the rise in public healthcare expenditure works out 
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292 mistic “Healthy ageing” scenario and the most pessimistic “Pure ageing” scenario 
amounts to a good 0.7% of GDP in 2045. This is the equivalent of 15% of all 
expenditure of the public sector in the reference year 2045, or an inflation-adjust-
ed CHF 7.7 billion. 
The strongest impact on the development of public healthcare expenditure can be 
seen with a change in hypotheses concerning: (i) the relationship between the 
increase in the population’s life expectancy and its state of health, and (ii) the 
assumption of a Baumol effect in the HeL sector. If it is assumed that while the 
population may be older in the future, it will be neither healthier nor less in need 
of care than the present population (“Pure ageing” scenario), expenditure as a 
percentage of GDP rises by almost a third compared to the “Reference scenario” 
in 2045 (+0.4% of GDP). By contrast, if the population lives out its additional 
years of life in good health and does not require care during these years (“Healthy 
ageing” scenario), the increase in expenditure is around a third lower than in the 
“Reference scenario” (-0.4% of GDP). Government expenditure rises slightly 
more than in the “Pure ageing” scenario if a substantial Baumol effect of 60% is 
assumed for HeL, together with lower productivity advances in the sector of long-
term care from the age of 65 (25% of average advance in productivity (“Expanded 
Baumol” scenario). The rise in expenditure works out almost as strong if a slight-
ly weaker Baumol effect in the HeL sector is assumed, namely 40%, together with 
a complete Baumol effect in long-term care (“Baumol” scenario). A rise in 
expenditure compared to the “Reference scenario” is likewise evident (+0.2% 
of GDP) if stronger cost pressure on the part of non-demographic determinants 
is assumed (“Cost pressure” scenario), such as advances in medical technology. 
A higher net immigration rate than in the reference scenario (“Migration” sce-
nario) has a slightly cost-restraining effect. 
Overall, demographic change is more significant for public healthcare expenditure 
than it is for total healthcare expenditure. The reason for this is that the proportion 
of public expenditure accounted for by long-term care from the age of 65 is 23%, 
much higher than in the overall healthcare sector (just under 15%). Accordingly, a 
change in the state of health against a backdrop of increasing life expectancy has 
significant repercussions for general government expenditure. A change in non-
demographic cost drivers (Baumol effect, income effect) has a particularly strong 
impact on general government expenditure in the hospitals sector. At around 40%, 
the share of public sector expenditure accounted for by hospitals is currently rela-
tively high when compared to the equivalent percentage of hospital expenditure 
for healthcare as a whole (just under 28%). 
4.3 ManDatoRY HealtHcaRe InsURance (MHI) eXPenDItURe
For the purposes of the projections, MHI expenditure in the sectors of healthcare 
excluding long-term care and long-term care from the age of 65 is broken down 
into outpatient and inpatient services. For the base year, the breakdown of expendi-
ture has been taken from the statistics of the Federal Statistical Office “Healthcare 
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293problem of duplicating general government expenditure, MHI expenditure is pre-
sented after the deduction of individual premium reduction (IPR) expenditure. In 
addition, the cost contributions of private households (deductible, co-payments) 
has been deducted.
Although the starting level is at roughly the same level as for public healthcare 
expenditure (3.3% vs. 3.5% of GDP), MHI expenditure rises only half as much by 
2045 (+0.8% vs. +1.5% of GDP). The latter is attributable to the fact that the pro-
portion of dynamically developing long-term care expenditure is much lower for 
MHI (9%) than it is for the general government (23%) in the reference year 2013. 
When viewed by sector, the lion’s share of the rise in expenditure in MHI by 2045, 
or +0.5% of GDP, is attributable to the HeL sector. The remaining increase of 
+0.3% of GDP is accounted for by long-term care from the age of 65.
Due to the high proportion of expenditure on healthcare excluding long-term care, 
MHI expenditure reacts very sensitively to changes in assumptions regarding the 
Baumol effect and other non-demographic cost drivers such as advances in medi-
cal technology (see figure 6). The stronger the Baumol effect in the HeL sector, the 
higher the rise in expenditure vis-à-vis the “Reference scenario”. Accordingly, the 
increase in MHI expenditure in the “Expanded Baumol” scenario is 0.7% of GDP 
higher than in the “Reference scenario”, while in the “Baumol” scenario it is 0.5% 
of GDP higher than in the “Reference scenario”. 
Figure 6






Reference Pure ageing Healthy ageing Migration



































Higher pressure on costs, as would be the case as a result of advances in medical 
technology (“Cost pressure” scenario), for example, leads to a rise in expenditure 
of 0.3% of GDP. Expenditure rises similarly strongly if the assumptions regarding 
the development of the population’s state of health and its need for care (“Pure 
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294 “Healthy ageing” scenario has an impact on the projections of a similar magnitude 
as in the “Pure ageing” scenario, but in this case it has a cost-restraining impact. 
4.4 coMPaRIson WItH otHeR stUDIes
The OECD presents projections of public HCE including the social health insur-
ance for the member states of the OECD including Switzerland (de la Maison-
neuve and Oliveira Martins, 2013). Whereas the OECD’s projections of public 
expenditure on LTC from the age of 65 are very similar to the projections of this 
paper, the OECD projects a stronger rise in expenditure in the HeL sector. The 
OECD shows a rise in public HCE from 6.9% (average of years 2006-2010) to 
9.5% of GDP for the year 2030 in the “Cost pressure” scenario, which assumes 
“no-policy change” (de la Maisonneuve and Oliveira Martins, 2013). In contrast, 
we project an increase in public HCE including MHI from 6.8% to 7.9% of GDP 
for the period from 2013 to 2030 in our “Reference scenario”. A key aspect for the 
upward deviation is the modelling of medical advances. While medical advances 
are tied to the economic development through income elasticity in our projections, 
the OECD uses a residual approach and assumes that the unexplained part of the 
regression with public HCE as dependent variable is caused by the costs for med-
ical advances. Moreover, the OECD uses an older more pessimistic population 
scenario and the base years differ. 
With respect to the methodology and the selected scenarios, our projections are 
even closer to the work of the EU AWG (2015). For example, in the “AWG refer-
ence scenario” the assumptions concerning the morbidity of the population are the 
same as in our “Reference scenario” (see AWG, 2015:124-25). 
Figure 7
Increase in public expenditure on healthcare and long-term care in an interna-
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295The increase in public HCE including MHI by 2.4% of GDP works out higher in 
Switzerland than the average increase of the EU-28 and the Eurozone with 1.7% 
of GDP respectively (see figure 7). In both sectors, HeL and LTC from the age of 
65 the expenditure increase in Switzerland outlast the one in the Eurozone by 
0.3% of GDP. The growth of public HCE including MHI is higher than in Ger-
many, and puts Switzerland between Austria and Denmark. The comparatively 
lower increase of public HCE in EU countries may be explained by the fact that 
EU AWG assumes that the income elasticity in HeL initially starts at 1.1 but con-
verges to 1.0 and that only a proportion of LTC services is affected by Baumol’s 
cost disease. In contrast, we assume a constant income elasticity of 1.1 and a full 
Baumol effect. Additionally, one should bear in mind that country-specific demo-
graphic scenarios, the expenditure profiles in the base year and the national health-
care systems differ.
5 DIscUssIon: MeasURes foR cost contaInMent
Our projections show that population ageing adds to the unrelenting pressure on 
public budgets and MHI. However, in particular, in the sector of HeL, non-demo-
graphic determinants such as medical advances and national income growth con-
tribute substantially to the dynamics of HCE. Demographic change affects the 
sector of LTC to a much greater degree than it does HeL. Since the LTC expendi-
ture share of the public sector substantially outweighs the share of MHI (23% vs. 
9%) population ageing affects the public sector stronger than MHI. As a result, a 
change in morbidity caused by an increasing life expectancy has a stronger impact 
on public finances. Therefore, the healthy ageing of the population is a crucial 
factor in alleviation of the cost burden on, particularly, public budgets. Accord-
ingly, preventive measures such as improving nutrition and mobility habits and 
the strengthening of the population health’s competencies that contribute to reduc-
ing chronic conditions are particularly important measures for cost containment. 
In addition, the different scenarios suggest that the pressure deriving from Bau-
mol’s cost disease is high. In such cases, efficiency-enhancing tools can prove 
particularly effective in reducing the pressure on MHI and public budgets. 
Measures that help to avoid medically unnecessary treatments, improve the allo-
cation of resources between outpatient and inpatient care and foster ambulatory 
and informal care to reduce the overcrowding of nursing homes can be effective. 
Given the coming demand for healthcare professionals, forward-looking person-
nel planning and the corresponding training of a sufficient number of healthcare 
professionals will be needed if costs are to be contained and the level of supply 
maintained (Merçay, Burla and Widmer, 2016). 
Recent studies on cost-containment policies by Moreno-Serra (201 ) and Schwi-
erz (2016) suggest that supply side reforms such as more reliance on capitation-
based fees, introducing budget caps and pharmaceutical policies can contribute to 
the mitigation of HCE growth. Budget caps can be introduced sector-wise or 
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296 ing. The main advantage of budget caps is that providers assume a budget respon-
sibility that currently does virtually not apply to Swiss healthcare providers. How-
ever, budget caps may increase the risk of rationing and increased waiting times 
or increased referrals for secondary level healthcare institutions instead of treat-
ment (e.g. Mihaljek, 2006; 2008 for specific country experiences). While in 2012 
the per-diem rates in hospitals were replaced by diagnosis-related groups (Swiss 
DRG), practicing physicians are still remunerated by fee-for-services. This creates 
incentives for an over-supply of medically unnecessary treatments and reinforces 
the problem of supplier-induced demand due to asymmetric information between 
providers and patients. The introduction of capitation-based fees can reduce these 
incentives. On the demand side, a stronger role of the general practitioner as gate-
keeper and the introduction of preferred drug lists have some success with respect 
to cost savings (Moreno-Serra, 2014). Ultimately, health technology assessment 
(HTA) that reviews treatments and drugs systematically may help to enhance the 
efficiency of healthcare and, as a result, curb costs. 
Disclosure statement 
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297aPPenDIX
Figure a1



































































Contributions to the inflation-adjusted rise in expenditure on long-term care (from 
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